Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c

Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.82, $0.09 better than the analyst estimate of $1.73. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.21 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2023 EPS of $7.95-$8.25, versus the consensus of $8.00. Total revenues are expected to increase by approximately 2% at reported rates and approximately 2% excluding foreign exchange.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Bristol-Myers Squibb Co. (BMY) PT Raised to $82 at Piper Sandler
• Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance
• Intuit holds investor day, reaffirms fiscal 2027 guidance